건선 환자에서 Secukinumab 치료 중 진단된 폐암 1예 = A Case of Lung Cancer Diagnosed during Secukinumab Treatment in a Patient with Psoriasis

다국어 초록 (Multilingual Abstract)

Psoriasis is a chronic inflammatory skin disease that affects the health and quality of life of patients. Biologics including interleukin-17A inhibitors have shown good efficacy and tolerable safety in patients with moderate-to-severe psoriasis. A 58-year-old man presented with mild pruritic multiple papules and plaques with scales on his whole body for more than 30 years. The patient diagnosed with psoriasis had been treated with phototherapy for more than 3 months, but the skin symptoms were rather aggravated, so secukinumab treatment was introduced. The patient’s skin lesions improved rapidly, and secukinumab treatment was continued without any adverse events for several years.
However, 62 months later, the patient informed that he was diagnosed with lung cancer and had undergone surgery.
Since then, the patient discontinued secukinumab treatment and has been treated with topical agents. Herein, we report a case of lung cancer diagnosed during secukinumab treatment in a patient with psoriasis.

참고문헌 (Reference)

1 석승휘 ; 안지혜 ; 이선구 ; 이희정 ; 윤문수 ; 김동현, "건선관절염을 동반한 건선 환자에서 adalimumab 치료 중 발생한 급성골수성백혈병 1예" 대한건선학회 15 (15): 59-61, 2018

2 최고운 ; 김동현, "건선 환자에서 Guselkumab 치료 중 발생한 후두암" 대한건선학회 18 (18): 39-42, 2021

3 Lebwohl M, "The risk of malignancy in patients with secukinumabtreated psoriasis, psoriatic arthritis and ankylosing spondylitis : analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up" 185 : 935-944, 2021

4 Zou W, "T(H)17 cells in tumour immunity and immunotherapy" 10 : 248-256, 2010

5 Martin-Orozco N, "T helper 17 cells promote cytotoxic T cell activation in tumor immunity" 31 : 787-798, 2009

6 Van De Kerkhof PC, "Secukinumab long-term safety experience : A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis" 75 : 83-98. e84, 2016

7 Genovese MC, "Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials" 59 : 3834-3844, 2020

8 Naldi L, "Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics : facts and controversies" 28 : 88-92, 2010

9 Bade BC, "Lung Cancer 2020 : Epidemiology, Etiology, and Prevention" 41 : 1-24, 2020

10 Papp KA, "Long-term safety of ustekinumab in patients with moderateto-severe psoriasis : final results from 5 years of follow-up" 168 : 844-854, 2013

11 Blauvelt A, "Consistent safety profile with up to 5 years of continuous treatment with guselkumab : Pooled analyses from the phase 3 VOYAGE 1and VOYAGE 2 trials of patients with moderate-to-severe psoriasis" 86 : 827-834, 2022

12 Jung SW, "Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center" 10 : 2022

13 Shear NH, "Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis : A network metaanalysis of clinical trial data" 85 : 572-581, 2021

14 Lee JH, "Cancer risk in 892 089 patients with psoriasis in Korea : A nationwide population-based cohort study" 46 : 95-102, 2019

15 Chai EZ, "Analysis of the intricate relationship between chronic inflammation and cancer" 468 : 1-15, 2015